糖尿病心血管并发症药物分子靶向递送系统的研究进展

刘妍 ,  秦小江 ,  魏成杰 ,  江雪露 ,  郑志发 ,  彭晓阳 ,  赵良渊 ,  施熠炜 ,  侯晓敏

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (6) : 808 -820.

PDF (10370KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (6) : 808 -820. DOI: 10.12092/j.issn.1009-2501.2026.06.010

糖尿病心血管并发症药物分子靶向递送系统的研究进展

作者信息 +

Research progress on drug molecular targeted delivery systems for cardiovascular complications of diabetes

Author information +
文章历史 +
PDF (10618K)

摘要

糖尿病(diabetes mellitus,DM)是一种以慢性高血糖为主要特征的代谢性疾病,其病理特征表现为碳水化合物、蛋白质和脂肪代谢紊乱。该疾病可引发大血管病变和微血管病变,进而导致多种严重并发症,如糖尿病神经病变、糖尿病肾病、糖尿病视网膜病变等。心血管并发症是其重要并发症之一,是导致糖尿病患者预后不良、致残率和死亡率升高的关键因素,临床表现涵盖冠心病、糖尿病性心肌病及心血管自主神经病变等多种病理情况。目前临床治疗方案包括血糖调控、血压管理、血脂调节、生活方式干预以及药物治疗等,传统药物递送系统存在显著局限性,具体表现为个体间药效学差异显著、药代动力学参数不理想、长期用药安全性问题突出、靶标特异性不足以及给药途径受限等。随着纳米技术与分子生物学研究的深入,基于高效靶向药物递送系统的治疗策略在糖尿病心血管并发症领域展现出广阔的应用前景,其中高效靶向药物递送系统的研发已成为该领域的重点研究方向。本综述系统梳理了糖尿病心血管并发症靶向治疗的最新研究进展,重点探讨了纳米载体技术、特异性靶向分子设计、智能响应型递送系统以及基因治疗等前沿领域的研究成果,旨在阐明分子靶向递送系统的临床转化价值,并为新型治疗策略的开发提供理论依据和研究思路。

Abstract

Diabetes mellitus (DM) is a metabolic disorder characterized primarily by chronic hyperglycemia, with pathological features including disorders of carbohydrate, protein, and fat metabolism. This disease can lead to macrovascular and microvascular complications, resulting in various severe complications, such as diabetic neuropathy, diabetic nephropathy, and diabetic retinopathy. Cardiovascular complications are one of the major complications, serving as a key factor contributing to poor prognosis, increased disability rates, and mortality in diabetic patients. Clinical manifestations include coronary heart disease, diabetic cardiomyopathy, and cardiovascular autonomic neuropathy, among other pathological forms. Current clinical treatment options include blood glucose control, blood pressure management, lipid regulation, lifestyle interventions, and drug therapy. Traditional drug delivery systems have significant limitations, including marked interindividual differences in pharmacodynamics, suboptimal pharmacokinetic parameters, prominent long-term safety issues, insufficient target specificity, and limited administration routes. With the advancement of nanotechnology and molecular biology research, treatment strategies based on efficient targeted drug delivery systems have shown great potential in the field of diabetic cardiovascular complications. The development of efficient targeted drug delivery systems has become a key research direction in this field. This review systematically summarizes the latest research progress in targeted therapy for diabetic cardiovascular complications, focusing on the research achievements in cutting-edge fields such as nanocarrier technology, specific targeting molecule design, smart responsive delivery systems, and gene therapy. The aim is to elucidate the clinical translational value of molecular targeted delivery systems and provide theoretical basis and research insights for the development of novel therapeutic strategies.

关键词

关键词 糖尿病 / 心血管并发症 / 分子靶向递送系统 / 纳米颗粒

Key words

KEYWORDS diabetes / cardiovascular complications / molecular targeted delivery systems / nanoparticles

引用本文

引用格式 ▾
刘妍,秦小江,魏成杰,江雪露,郑志发,彭晓阳,赵良渊,施熠炜,侯晓敏. 糖尿病心血管并发症药物分子靶向递送系统的研究进展[J]. 中国临床药理学与治疗学, 2026, 31(6): 808-820 DOI:10.12092/j.issn.1009-2501.2026.06.010

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

国家心血管病中心, 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告 2024 概要[J].中国循环杂志, 2025, 40(6): 521-59.

[2]

Wang W, Qiao J, Zhang L, et al. Prevalence of very high cardiovascular disease risk in patients with type 2 diabetes mellitus: a population-based cross-sectional screening study[J].Diabetes Obes Metab, 2024, 26(10): 4251-4260.

[3]

Kaushal A, Musafir A, Sharma G, et al. Revolutionizing diabetes management through nanotechnology-driven smart systems[J].Pharmaceutics, 2025, 17(6): 680.

[4]

Shi Y, Dong M, Wu Y, et al. An elastase-inhibiting, plaque-targeting and neutrophil-hitchhiking liposome against atherosclerosis[J].Acta Biomater, 2024, 173: 470-481.

[5]

Lobatto ME, Fayad ZA, Silvera S, et al. Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis[J].Mol Pharm, 2010, 7(6): 2020-2029.

[6]

Sharifi S, Seyednejad H, Laurent S, et al. Superparamagnetic iron oxide nanoparticles for in vivo molecular and cellular imaging[J].Contrast Media Mol Imaging, 2015, 10(5): 329-355.

[7]

Chen X, Tohme M, Park R, et al. Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide[J].Mol Imaging, 2004, 3(2): 96-104.

[8]

Hu CM, Zhang L, Aryal S, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform[J].Proc Natl Acad Sci U S A, 2011, 108(27): 10980-10985.

[9]

George TA, Hsu CC, Meeson A, et al. Nanocarrier-based targeted therapies for myocardial infarction[J].Pharmaceutics, 2022, 14(5): 1020.

[10]

Pala R, Anju VT, Dyavaiah M, et al. Nanoparticle-mediated drug delivery for the treatment of cardiovascular diseases[J].Int J Nanomedicine, 2020, 15: 3741-3769.

[11]

Shariati L, Esmaeili Y, Rahimmanesh I, et al. Advances in nanobased platforms for cardiovascular diseases: Early diagnosis, imaging, treatment, and tissue engineering[J].Environ Res, 2023, 238(Pt 1): 116933.

[12]

Li D, Taylor A, Shi H, et al. Peptide-guided nanoparticle drug delivery for cardiomyocytes[J].Biology (Basel), 2024, 13(1): 14.

[13]

Han X, Alameh MG, Xu Y, et al. Optimization of the activity and biodegradability of ionizable lipids for mRNA delivery via directed chemical evolution[J].Nat Biomed Eng, 2024, 8(11): 1412-1424.

[14]

Km V, Vijay K, Arvind R.Advancements in herbal-nano formulations: A systematic review[J].Educ Adm Theory Pract, 2024, 30(5): 11099-110109.

[15]

Prajnamitra RP, Chen HC, Lin CJ, et al. Nanotechnology approaches in tackling cardiovascular diseases[J].Molecules, 2019, 24(10): 2017.

[16]

郑蕊, 屠叶清, 王慧, 等. PLGA 作为抗原递送系统的研究进展[J].中国生物工程杂志, 2023, 43(05): 69-75.

[17]

Chang MY, Yang YJ, Chang CH, et al. Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction[J].J Control Release, 2013, 170(2): 287-294.

[18]

Catuogno S, Esposito CL, De Franciscis V. Aptamer-mediated targeted delivery of therapeutics: an update[J].Pharmaceuticals (Basel), 2016, 9(4): 69.

[19]

Scafa Udriște A, Burdușel AC, Niculescu AG, et al. Metal-based nanoparticles for cardiovascular diseases[J].Int J Mol Sci, 2024, 25(2): 1001.

[20]

Zheng Q, Chen C, Liu Y, et al. Metal nanoparticles: advanced and promising technology in diabetic wound therapy[J].Int J Nanomedicine, 2024, 19: 965-992.

[21]

Abdelkawi A, Slim A, Zinoune Z, et al. Surface modification of metallic nanoparticles for targeting drugs[J].Coatings, 2023, 13(9): 1560.

[22]

王斐, 陈要臻, 胡兴斌. 抗 CD-38 和抗 CD-47 单抗药物对输血相容性检测的干扰与应对策略研究进展[J].临床输血与检验, 2023, 25(4): 559-564.

[23]

Kaplon H, Crescioli S, Chenoweth A, et al. Antibodies to watch in 2023[J].MAbs, 2023, 15(1): 2153410.

[24]

Yang Y, Zou H.Research progress on Nrf2 intervention in the treatment of diabetic retinopathy[J].Front Endocrinol (Lausanne), 2025, 16: 1587231.

[25]

Zhang C, Huang J, Yang P, et al. [Irisin Alleviates Inflammatory Injury in Diabetic Cardiomyopathy by Regulating NF-κB Pathway][J].Sichuan Da Xue Xue Bao Yi Xue Ban, 2023, 54: 3: 545-551.

[26]

Ye W, Han K, Xie M, et al. Mitochondrial energy metabolism in diabetic cardiomyopathy: Physiological adaption, pathogenesis, and therapeutic targets[J].Chin Med J (Engl), 2024, 137(8): 936-948.

[27]

李思楠, 王玺, 安宇, 等. 植物源生物活性肽的制备、生理活性及作用机制研究进展[J].食品工业科技, 2025, 46(03): 394-402.

[28]

Ma X, Chuang PH, Tseng YH, et al. Progress in research on animal collagen peptides: preparation, bioactivity, and application[J].Molecules, 2025, 30(15): 3520.

[29]

Kim B, Kim YS, Li W, et al. Ginsenoside Rg5, a potent agonist of Nrf2, inhibits HSV-1 infection-induced neuroinflammation by inhibiting oxidative stress and NF-κB activation[J].J Ginseng Res, 2024, 48(4): 384-394.

[30]

Zhang J, Ji C, Zhai X, et al. Frontiers and hotspots evolution in anti-inflammatory studies for coronary heart disease: a bibliometric analysis of 1990-2022[J].Front Cardiovasc Med, 2023, 10: 1038738.

[31]

Bachheti RK, Worku LA, Gonfa YH, et al. Prevention and treatment of cardiovascular diseases with plant phytochemicals: a review[J].Evid Based Complement Alternat Med, 2022, 2022: 5741198.

[32]

Yang P, Liu M, Fan X, et al. Recent advances in natural plant-based treatment of myocardial ischemia-reperfusion injury[J].Int J Drug Discov Pharmacol, 2023, 2(1): 1009.

[33]

周高峰, 肖静, 周佳, 等. 鹿茸多肽预处理通过 miR-133a 调控 TGF-β/Smad 信号通路对 TBHP 诱导心肌 H9c2 细胞损伤的保护作用[J].吉林大学学报 (医学版), 2023, 49(2): 369-376.

[34]

Soltani D, Azizi B, Rahimi R, et al. Mechanism-based targeting of cardiac arrhythmias by phytochemicals and medicinal herbs: a comprehensive review of preclinical and clinical evidence[J].Front Cardiovasc Med, 2022, 9: 990063.

[35]

Hesari M, Mohammadi P, Khademi F, et al. Current advances in the use of nanophytomedicine therapies for human cardiovascular diseases[J].Int J Nanomedicine, 2021, 16: 3293-3315.

[36]

Yuan S, Ma T, Zhang YN, et al. Novel drug delivery strategies for antidepressant active ingredients from natural medicinal plants: the state of the art[J].J Nanobiotechnology, 2023, 21(1): 391.

[37]

Alotaibi BS, Ijaz M, Buabeid M, et al. Therapeutic effects and safe uses of plant-derived polyphenolic compounds in cardiovascular diseases: a review[J].Drug Des Devel Ther, 2021, 15: 4713-4732.

[38]

De Abreu RC, Fernandes H, Da Costa Martins PA, et al. Native and bioengineered extracellular vesicles for cardiovascular therapeutics[J].Nat Rev Cardiol, 2020, 17(11): 685-697.

[39]

Wang X, Chen Y, Zhao Z, et al. Engineered exosomes with ischemic myocardium-targeting peptide for targeted therapy in myocardial infarction[J].J Am Heart Assoc, 2018, 7(15): e008737.

[40]

Huang L, Wu E, Liao J, et al. Research advances of engineered exosomes as drug delivery carrier[J].ACS Omega, 2023, 8(46): 43374-43387.

[41]

李旻俊, 彭泽琳, 张良清. 外泌体药物递送载体构建及治疗心血管疾病的研究进展[J].中华实用诊断与治疗杂志, 2021, 35(7): 746-749.

[42]

Kim H, Yun N, Mun D, et al. Cardiac-specific delivery by cardiac tissue-targeting peptide-expressing exosomes[J].Biochem Biophys Res Commun, 2018, 499(4): 803-808.

[43]

Song Y, Zhang C, Zhang J, et al. Localized injection of miRNA-21-enriched extracellular vesicles effectively restores cardiac function after myocardial infarction[J].Theranostics, 2019, 9(8): 2346-2360.

[44]

Okamura A, Yoshioka Y, Saito Y, et al. Can extracellular vesicles as drug delivery systems be a game changer in cardiac disease?[J].Pharm Res, 2023, 40(4): 889-908.

[45]

Bu T, Li Z, Hou Y, et al. Exosome-mediated delivery of inflammation-responsive IL-10 mRNA for controlled atherosclerosis treatment[J].Theranostics, 2021, 11(20): 9988-10000.

[46]

Rao D, Huang D, Sang C, et al. Advances in mesenchymal stem cell-derived exosomes as drug delivery vehicles[J].Front Bioeng Biotechnol, 2021, 9: 797359.

[47]

Luo T, Zhang Z, Xu J, et al. Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms[J].Front Bioeng Biotechnol, 2023, 11: 1205751.

[48]

李祥子, 胡平静, 朱振铎, 等. pH 响应型纳米药物载体的释药机制及性能研究进展[J].无机化学学报, 2018, 34(8): 1399-1412.

[49]

Sung HW, Sonaje K, Liao ZX, et al. pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications[J].Acc Chem Res, 2012, 45(4): 619-629.

[50]

Liu Y, Zeng S, Ji W, et al. Emerging theranostic nanomaterials in diabetes and its complications[J].Adv Sci (Weinh), 2022, 9(3): e2102466.

[51]

Zhang YJ, Zhan X, Wang L, et al. pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model[J].J Pharm Sci, 2015, 104(5): 1815-1824.

[52]

Ma Q, Bian L, Zhao X, et al. Novel glucose-responsive nanoparticles based on p-hydroxyphenethyl anisate and 3-acrylamidophenylboronic acid reduce blood glucose and ameliorate diabetic nephropathy[J].Mater Today Bio, 2022, 13: 100181.

[53]

易聪华, 徐青荷, 王淼, 等. pH 敏感性生物基纳米载药粒子的研究进展[J].化工进展, 2021, 40(6): 3411-3420.

[54]

武小东. 多功能载药纳米胶束的结构设计与制备及其在动脉粥样硬化诊疗应用中的研究[D].长春:吉林大学, 2021.

[55]

Sullivan HL, Liang Y, Worthington K, et al. Enzyme-responsive nanoparticles for the targeted delivery of an MMP inhibitor to acute myocardial infarction[J].Biomacromolecules, 2023, 24(11): 4695-4704.

[56]

王娜, 杨丽霞. 细胞外基质金属蛋白酶诱导因子与心血管疾病[J].国际心血管病杂志, 2024, 51(6): 356-359.

[57]

Xiao Z, Li Y, Xiong L, et al. Recent advances in anti-atherosclerosis and potential therapeutic targets for nanomaterial-derived drug formulations[J].Adv Sci (Weinh), 2023, 10(29): e2302918.

[58]

Kumar G, Saini M, Kundu S. Therapeutic enzymes as non-conventional targets in cardiovascular impairments: a comprehensive review[J].Can J Physiol Pharmacol, 2022, 100(3): 197-209.

[59]

Liu H, Pietersz G, Peter K, et al. Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis[J].J Nanobiotechnology, 2022, 20(1): 75.

[60]

Omidian H, Babanejad N, Cubeddu LX. Nanosystems in cardiovascular medicine: advancements, applications, and future perspectives[J].Pharmaceutics, 2023, 15(7): 1935.

[61]

Zhang Y, Li Y, Huang X, et al. Systemic delivery of siRNA specific for silencing TLR4 gene expression reduces diabetic cardiomyopathy in a mouse model of streptozotocin-induced type 1 diabetes[J].Diabetes Ther, 2020, 11(5): 1161-1173.

[62]

熊凌, 郭昆全, 宋文英. AIM2 基因沉默对糖尿病大鼠心肌损伤的影响机制[J].贵州医科大学学报, 2021, 46(1): 44-50.

[63]

Sundaramoorthy A, Jafar Ali D, Shanmugam N. Inflammatory gene silencing in activated monocytes by a cholesterol tagged-miRNA/siRNA: a novel approach to ameliorate diabetes induced inflammation[J].Cell Tissue Res, 2022, 389(2): 219-240.

[64]

Moazzam M, Zhang M, Hussain A, et al. The landscape of nanoparticle-based siRNA delivery and therapeutic development[J].Mol Ther, 2024, 32(2): 284-312.

[65]

Pellegrini V, La Grotta R, Carreras F, et al. Inflammatory trajectory of type 2 diabetes: novel opportunities for early and late treatment[J].Cells, 2024, 13(19): 1620.

[66]

Shrivastav D, Singh DD. Emerging roles of microRNAs as diagnostics and potential therapeutic interest in type 2 diabetes mellitus[J].World J Clin Cases, 2024, 12(3): 525-537.

[67]

Ding Y, Sun X, Shan PF.MicroRNAs and cardiovascular disease in diabetes mellitus[J].Biomed Res Int, 2017, 2017: 4080364.

[68]

Das A, Samidurai A, Salloum FN.Deciphering non-coding RNAs in cardiovascular health and disease[J].Front Cardiovasc Med, 2018, 5: 73.

[69]

Szydełko J, Matyjaszek-Matuszek B. MicroRNAs as biomarkers for coronary artery disease related to type 2 diabetes mellitus: from pathogenesis to potential clinical application[J].Int J Mol Sci, 2022, 24(1): 562.

[70]

Dehaini H, Awada H, El-Yazbi A, et al. MicroRNAs as potential pharmaco-targets in ischemia-reperfusion injury compounded by diabetes[J].Cells, 2019, 8(2): 152.

[71]

Deng J, Liao Y, Liu J, et al. Research progress on epigenetics of diabetic cardiomyopathy in type 2 diabetes[J].Front Cell Dev Biol, 2021, 9: 777258.

[72]

Kankuri E. Positive feedback loop of miR-320 and CD36 regulates the hyperglycemic memory-induced diabetic diastolic cardiac dysfunction[J].Mol Ther Nucleic Acids, 2023, 32: 318-321.

[73]

Tudurachi BS, Anghel L, Tudurachi A, et al. Unraveling the cardiac matrix: from diabetes to heart failure, exploring pathways and potential medications[J].Biomedicines, 2024, 12(6): 1250.

[74]

Lezoualc'h F, Badimon L, Baker H, et al. Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality[J].Cardiovasc Res, 2023, 119(5): 1130-1145.

[75]

张笑涵, 刘乃需, 钦扬, 等. 基于整合用药及靶点网络探讨中药治疗 2 型糖尿病合并高脂血症的核心处方及作用机制[J].药物评价研究, 2023, 46(11): 2309-2320.

[76]

Tu L, Zou Z, Yang Y, et al. Targeted drug delivery systems for atherosclerosis[J].J Nanobiotechnology, 2025, 23(1): 306.

[77]

Mimouni M, Lajoix AD, Desmetz C. Experimental models to study endothelial to mesenchymal transition in myocardial fibrosis and cardiovascular diseases[J].Int J Mol Sci, 2023, 25(1): 380.

基金资助

国家自然科学基金青年项目(82204042)

国家自然科学基金面上项目(82373622)

山西省科技创新人才团队(青年)项目(202304051001038)

山西省科技合作交流专项项目(区域合作项目)(2022040411022)

国家卫生健康委员会尘肺病重点实验室开放课题(NHC202307)

山西省高等教育“百亿工程”科技引导专项(BYJL067)

AI Summary AI Mindmap
PDF (10370KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉